

Press Release

Ajanta Pharma Posts Yet Another Sound Performance

Mumbai - (April 30, 2013) - Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has announced its results today for the quarter and year ended March 31st 2013 with yet another sound performance.

Highlights of Q4 FY13 standalone financial performance

- Revenue from operations at Rs.249crs (Rs.176crs), growth of 42% over Q4 last year
- Other income includes dividend of Rs.5.42crs received from Mauritius subsidiary
- EBITDA at Rs.68crs (Rs.41crs), growth of 66% over same quarter last year
- Tax expenses for the quarter includes one-time expense of Rs.15.75crs (Rs. Nil) arising due to filing of revised returns for earlier years
- Profit after Tax at Rs.27crs (Rs.24crs), growth of 15% over same quarter last year
- Exports contributed 71% of the total operating income for the quarter

Highlights of FY13 standalone financial performance

- Revenue from operations at Rs.839crs (Rs.604crs), growth of 39% over previous year
- EBITDA at Rs.207crs (Rs.123crs), growth of 68% over previous year
- Profit after Tax at Rs.101crs (Rs.66crs), growth of 52% over previous year, after considering one-time tax for earlier years as mentioned above
- Exports contributed 64% of the total operating income for the year

Highlights of FY13 consolidated financial performance

- Revenue from operations at Rs.931crs (Rs.677crs), growth of 37% over the previous year
- EBITDA at Rs.224crs (Rs.137crs), growth of 64% over the previous year
- Profit after Tax at Rs.112crs (Rs.77crs), growth of 45% over the previous year

Commenting on the results, Mr. Yogesh Agrawal, Managing Director said "Sound results for the quarter & the year demonstrates our comprehensive strategic planning, robust execution capability and strong management bandwidth. We have been consistently making an effort to move up the value chain in business quality by developing challenging complex products & building brands across geographies".

Ajanta Pharma filed 3 more ANDAs with USFDA during the quarter, which takes the basket of ANDAs to 14 (2 approved and 12 waiting for approval).



INVESTOR CONTACTS:

Deodatta Pandit, Company Secretary
+91 22 66061203 Email : deodatta.pandit@ajantapharma.com

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company. Ranked 45th in the Indian formulation market (IMS MAT Mar'13), company has leading brands in therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of company's products are first in the market place kind and are leading in their sub therapeutic segments. Company has a well established branded generic business in emerging markets of Asia, Africa and Latin America. It has recently entered in the regulated markets of USA and is building a portfolio of ANDAs for this market. It has also received marketing authorization in 11 EU countries including UK, for one of its product.

For last 10 years, company's consolidated performance has been outstanding with CAGR of 23% in revenue and 53% in net profit.

Ajanta Pharma has its State of the Art R&D centre for formulation development, located at Mumbai, having a team of more than 250 people. Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius. One of the manufacturing facilities in India is approved by US FDA, UK MHRA, pre qualification from World health organisation (WHO), apart from having the approval from FDA of many other countries. Company is setting up two more manufacturing facilities in India, one for regulated markets and another for domestic and rest of the world markets. For more details please visit our website www.ajantapharma.com



INVESTOR CONTACTS:

Deodatta Pandit, Company Secretary
+91 22 66061203 Email : deodatta.pandit@ajantapharma.com